文献速递甲状腺疾病

新型生物标志物揭示胺碘酮诱导的甲状腺功能亢进症中组织与血清甲状腺激素状态不匹配

Novel Biomarkers Reveal Mismatch Between Tissue and Serum Thyroid Hormone Status in Amiodarone-Induced Hyperthyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究利用人类毛囊中甲状腺激素反应标志基因构建分类模型评估组织甲状腺激素作用,并在胺碘酮治疗患者及THAI小鼠中验证。结果显示在甲状腺功能减退和正常者中血清与毛囊状态一致,但在甲状腺功能亢进患者中胺碘酮降低两者一致性,提示胺碘酮诱导的甲状腺功能亢进症并非均与组织甲状腺功能亢进相关,THAI小鼠中胺碘酮可阻止组织甲状腺功能亢进而血清游离甲状腺素仍高。

要点

  • 基于毛囊标志基因的分类模型可较好预测组织甲状腺激素状态。
  • 胺碘酮诱导的甲状腺功能亢进症中血清与组织甲状腺激素状态常不一致。
  • 相当比例患者无组织甲状腺功能亢进,胺碘酮可能保护组织免受甲状腺毒症。

核心结论

  • 研究开发了微创的毛囊标志物方法评估组织甲状腺激素作用,可补充争议病例的常规诊断。
  • 相当比例胺碘酮诱导的甲状腺功能亢进症患者未发生组织甲状腺功能亢进,提示胺碘酮保护组织免受甲状腺毒症。
  • 评估组织甲状腺激素作用可能有助于胺碘酮诱导的甲状腺功能亢进症的治疗决策。

研究设计与样本

  • 从人类毛囊中用下一代测序鉴定甲状腺激素反应标志基因,并经定量聚合酶链反应验证。
  • 用这些标志物构建分类模型评估组织甲状腺激素作用,并应用于胺碘酮治疗患者。
  • 在甲状腺激素作用指示(THAI)小鼠中研究胺碘酮对组织甲状腺激素作用的影响。

主要发现

  • 分类模型经验证,预测受试者组织甲状腺激素状态表现良好。
  • 在甲状腺功能减退和甲状腺功能正常的胺碘酮治疗患者中,基于血清和基于毛囊的甲状腺激素状态一致。
  • 在甲状腺功能亢进患者中,胺碘酮降低基于血清和基于毛囊的甲状腺激素状态的一致性,表明胺碘酮诱导的甲状腺功能亢进症并非明确与组织甲状腺功能亢进相关。
  • 在THAI小鼠模型中,尽管血清游离甲状腺素高,胺碘酮阻止了组织甲状腺功能亢进,证实了上述发现。

临床怎么用

  • 作者认为,使用毛囊标志物的微创方法可补充争议病例的常规诊断。
  • 作者认为,评估胺碘酮诱导的甲状腺功能亢进症患者的组织甲状腺激素作用可能有助于治疗决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Serum thyrotropin and thyroid hormone (TH) levels are routine markers of thyroid function. However, their diagnostic performance is limited under special conditions, such as in amiodarone-induced hyperthyroidism (AIH). Such cases would require the assessment of tissue TH action, which is currently unfeasible. OBJECTIVE: Development of an approach that determines how well serum parameters are reflected in tissue TH action of patients. METHODS: TH-responsive marker genes were identified from human hair follicles (HFs) with next-generation sequencing, validated by quantitative polymerase chain reaction. A classification model was built with these markers to assess tissue TH action and was deployed on amiodarone-treated patients. The impact of amiodarone on tissue TH action was also studied in thyroid hormone action indicator (THAI) mice. RESULTS: The classification model was validated and shown to predict tissue TH status of subjects with good performance. Serum- and HF-based TH statuses were concordant in hypothyroid and euthyroid amiodarone-treated patients. In contrast, amiodarone decreased the coincidence of serum-based and HF-based TH statuses in patients with hyperthyroidism, indicating that AIH is not unequivocally associated with tissue hyperthyroidism. This was confirmed in the THAI model, where amiodarone prevented tissue hyperthyroidism in THAI mice despite high serum free thyroxine. CONCLUSION: We developed a minimally invasive approach using HF markers to assess tissue TH economy that could complement routine diagnostics in controversial cases. We observed that a substantial proportion of patients with AIH do not develop tissue hyperthyroidism, indicating that amiodarone protects tissues from thyrotoxicosis. Assessing tissue TH action in patients with AIH may be warranted for treatment decisions.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sinkó R, Katkó M, Tóth G, et al. Novel Biomarkers Reveal Mismatch Between Tissue and Serum Thyroid Hormone Status in Amiodarone-Induced Hyperthyroidism. J Clin Endocrinol Metab. 2025. PMID: 39076009. doi:10.1210/clinem/dgae514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。